Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes

Alfredo Pontecorvi, Antonio Bianchi, Antonella Giampietro, Linda Tartaglione, Sabrina Chiloiro, Laura De Marinis Grasso, Ferdinando Valentini, Raffaella Iuorio, Maurizio Poggi, Roberto Baldelli, Marina Passeri, Marialuisa Appetecchia, Patrizia Gargiulo, Andrea Fabbri, Vincenzo Toscano

Risultato della ricerca: Contributo in rivistaArticolo in rivista

30 Citazioni (Scopus)

Abstract

Pegvisomant (PEGV) is widely used, alone or with somatostatin analogs (SSA), for GH-secreting pituitary tumors poorly controlled by SSAs alone. No information is available on specific indications for or relative efficacies of PEGV+SSA versus PEGV monotherapy. Aim of our study was to characterize real-life clinical use of PEGV vs. PEGV+SSA for SSA-resistant acromegaly (patient selection, long-term outcomes, adverse event rates, doses required to achieve control).
Lingua originaleEnglish
pagine (da-a)40-40
Numero di pagine1
RivistaJOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Volume32
DOI
Stato di pubblicazionePubblicato - 2013

Keywords

  • Acromegaly
  • Adolescent
  • Adult
  • Aged
  • Antineoplastic Agents, Hormonal
  • Female
  • Growth Hormone-Secreting Pituitary Adenoma
  • Human Growth Hormone
  • Humans
  • Male
  • Middle Aged
  • Retrospective Studies
  • Somatostatin
  • Treatment Outcome
  • Young Adult

Fingerprint

Entra nei temi di ricerca di 'Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes'. Insieme formano una fingerprint unica.

Cita questo